Site Editor

Thomas Flaig, MD

Advertisement
Advertisement

ASCO 2022: Focus of SWOG S1937 in Metastatic Urothelial Carcinoma Is Eribulin With or Without Gemcitabine

By: Hope Craig, MSPH
Posted: Wednesday, June 22, 2022

At this year’s American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract TPS4608), a team of researchers shared methods for the phase III, randomized trial SWOG S1937. It will assess the regimens of eribulin, with and without gemcitabine, in comparison to the standard-of-care platinum-based chemotherapy for patients with bladder cancer.

Conducted by Sarmad Sadeghi, MD, PhD, of the University of Southern California Norris Comprehensive Cancer Center, and colleagues, the study includes three arms of patients with metastatic urothelial carcinoma refractory to or ineligible for PD-1/PD-L1 therapy (n = 465). They include eribulin (given at 1.4 mg/m2 on days 1 and 8 of a 21-day cycle), gemcitabine/eribulin (gemcitabine is added to eribulin at 1,000 mg/m2 on days 1 and 8), and the standard of care (docetaxel, paclitaxel, or gemcitabine). The study seeks to increase median overall survival to 10.5 months (hazard ratio = 0.667), assuming a median overall survival of 7 months for the standard-of-care arm.

The study builds on a phase I/II Cancer Therapy Evaluation Program (CTEP) study of eribulin for metastatic urothelial carcinoma, which demonstrated an overall response rate of 37.5%, median progression-free survival of 4.1 months, and overall survival of 9.5 months. Further, a phase II CTEP study of gemcitabine/eribulin in cisplatin ineligible–metastatic urothelial carcinoma showed an overall survival rate of 50%, median overall survival of 11.9 months, and progression-free survival of 5.3 months. The phase III randomized trial began in February 2021 and is ongoing.

Disclosure: Authors’ full disclosures are available at coi.asco.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.